{"id":30043,"date":"2025-08-13T19:57:22","date_gmt":"2025-08-13T19:57:22","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/the-rainwater-charitable-foundation-aging-mind-foundation-alzheimers-association-and-curepsp-join-forces-to-award-2-5-million-in-neurodegenerative-disease-research-grants-from-2025-tauopathy-cha\/"},"modified":"2025-08-13T19:57:22","modified_gmt":"2025-08-13T19:57:22","slug":"the-rainwater-charitable-foundation-aging-mind-foundation-alzheimers-association-and-curepsp-join-forces-to-award-2-5-million-in-neurodegenerative-disease-research-grants-from-2025-tauopathy-cha","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=30043","title":{"rendered":"The Rainwater Charitable Foundation, Aging Mind Foundation, Alzheimer&#8217;s Association, and CurePSP Join Forces to Award $2.5 Million in Neurodegenerative Disease Research Grants from 2025 Tauopathy Challenge Workshop"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2748989\/Tauopathy_Challenge_Workshop_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"prntac\"><i>Established in 2023, the Tauopathy Challenge Workshop aims to bridge the gap in funding of novel neurodegenerative research for primary tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs).<\/i><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">FORT WORTH, Texas<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 13, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=1918150831&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2F&amp;a=The+Rainwater+Charitable+Foundation\" target=\"_blank\" rel=\"nofollow\">The Rainwater Charitable Foundation<\/a>, one of the largest independent funders of primary tauopathy research, in collaboration with the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=235016787&amp;u=https%3A%2F%2Fagingmindfoundation.org%2F&amp;a=Aging+Mind+Foundation\" target=\"_blank\" rel=\"nofollow\">Aging Mind Foundation<\/a>, the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=3063617718&amp;u=https%3A%2F%2Fwww.alz.org%2F&amp;a=Alzheimer%27s+Association\" target=\"_blank\" rel=\"nofollow\">Alzheimer&#8217;s Association<\/a>, and <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=3061121997&amp;u=https%3A%2F%2Fwww.psp.org%2F&amp;a=CurePSP\" target=\"_blank\" rel=\"nofollow\">CurePSP<\/a>,\u00a0announced today <span class=\"xn-money\">$2.5 million<\/span> in grants to fund five innovative research projects over the course of two years emerging from the second annual <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=943107863&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2F2025-tauopathy-challenge-workshop-participants-will-explore-the-role-of-copathologies-in-primary-tauopathies%2F&amp;a=Tauopathy+Challenge+Workshop\" target=\"_blank\" rel=\"nofollow\">Tauopathy Challenge Workshop<\/a>.<\/p>\n<p>The Tauopathy Challenge Workshop is a funding program that convenes interdisciplinary experts around a single topic, addressing unmet needs in primary tauopathies. By funding innovative research, it aims to support the development of treatments for these debilitating neurodegenerative diseases, such as Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs).<\/p>\n<p>Growing in size and impact since its inception in 2023, the Tauopathy Challenge Workshop has awarded <span class=\"xn-money\">$4.5 million<\/span> to support novel, mechanism-focused research aimed at uncovering new therapeutic and biomarker targets for these tau-driven neurodegenerative diseases. This year, five groundbreaking projects will be funded and led by esteemed international researchers:<\/p>\n<ul type=\"disc\">\n<li><b>Eleanor\u00a0Drummond, PhD, <span class=\"xn-org\">University of Sydney<\/span><\/b>\u00a0<b>(Awarded <span class=\"xn-money\">$500,000<\/span>): <\/b>This research aims to uncover how abnormal protein aggregation beyond tau contributes to primary tauopathies, specifically PSP, CBD, and Pick&#8217;s disease. Using advanced molecular techniques, Dr. Drummond will identify proteins in the human brain prone to forming pathological aggregates and determine whether these changes are shared across different tauopathies. By mapping the location of these proteins in brain tissue and testing whether tau drives their aggregation, the study seeks to clarify disease mechanisms, identify biomarkers, and explore whether these processes can be reversed in cell models\u2014ultimately guiding future therapeutic strategies.<\/li>\n<li><b><span class=\"xn-person\">Leonard Petrucelli<\/span>, PhD, Mayo Clinic (Awarded <span class=\"xn-money\">$500,000<\/span>):\u00a0<\/b>This research explores whether lysosomal transmembrane protein <span class=\"xn-money\">106B<\/span> (TMEM106B) fibrils promote tau seeding and worsen PSP symptoms, by analyzing post-mortem brain samples and assessing correlations between protein levels, genetic variants, and disease severity. Using innovative tools in human neurons and mouse models, Dr. Petrucelli and his co-investigator, Dr. <span class=\"xn-person\">Michael Ward<\/span> (National Institutes of Health), will test whether TMEM106B fibrils directly influence tau pathology and lysosomal dysfunction, potentially uncovering new mechanisms and therapeutic targets for PSP.<\/li>\n<li><b><span class=\"xn-person\">Vijay Rangachari<\/span>, PhD, The <span class=\"xn-org\">University of Southern Mississippi<\/span> (Awarded <span class=\"xn-money\">$500,000<\/span>):\u00a0<\/b>This research examines the potential interaction between two amyloid-forming proteins\u2014transactive response DNA binding protein 43 kDa (TDP-43) and tau\u2014in neurodegenerative diseases such as PSP and frontotemporal lobar degeneration (FTLD). While both proteins are known to independently form toxic aggregates, the work explores whether they can co-aggregate into &#8220;hybrid amyloids&#8221; with unique structures and pathological effects. Dr. Rangachari aims to confirm the presence of these deposits in human brain tissue, understand their molecular characteristics, and assess their role in neuronal dysfunction\u2014with the hope of developing antibodies to detect these toxic agents in the brain.<\/li>\n<li><b>Wilfried Rossoll, PhD, Mayo Clinic (Awarded <span class=\"xn-money\">$500,000<\/span>): <\/b>This research aims to uncover how TDP-43 co-pathology influences tau pathology and contributes to neurodegeneration in PSP and CBD. By leveraging both innovative spatial proteomics discovery approaches in human post-mortem brain tissue and mechanistic studies in mouse brain tissue culture models, Dr. Rossoll will explore how these proteins interact and affect overall disease progression. Insights gained will pave the way for stronger tools for studying neurodegenerative disorders and developing effective treatments.<\/li>\n<li><b><span class=\"xn-person\">Mikael Simons<\/span>, MD, Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen, DZNE (German Center for Neurodegenerative Diseases) (Awarded <span class=\"xn-money\">$500,000<\/span>): <\/b>This research investigates how non-neuronal cells, particularly glial cells like oligodendrocytes, and factors such as myelin damage and lipoproteins (particularly ApoE), contribute to tau aggregation and propagation. Using advanced imaging, biochemical assays, and both mouse models and human brain tissue, Dr. Simons aims to uncover whether disruptions in myelin and lipid transport systems play a critical role in tau pathology. The goal is to deepen understanding of tau-related disorders and identify potential therapeutic targets.<\/li>\n<\/ul>\n<p>&#8220;We&#8217;re encouraged to see growing momentum around the Tauopathy Challenge Workshop, with partners such as the Aging Mind Foundation, the Alzheimer&#8217;s Association, and CurePSP joining our mission to support these novel, high impact proposals,&#8221; said <span class=\"xn-person\">Jeremy Smith<\/span>, President of the Rainwater Charitable Foundation. &#8220;Given the current constraints on research funding, our commitment remains steadfast in advancing primary tauopathy research. The insights gained from this workshop have the potential to significantly impact broader neurodegenerative disease research, bringing us closer to meaningful treatments for those affected.&#8221;<\/p>\n<p>The 2026 Tauopathy Challenge Workshop is open to all researchers through a letter of intent process, with <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=331493903&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2Fadditional-research-programs%2Fworkshop%2F&amp;a=applications\" target=\"_blank\" rel=\"nofollow\">applications<\/a>\u00a0for the next workshop open through <span class=\"xn-chron\">September 2, 2025<\/span>. The 2026 session is focused on exploring the structural and thermodynamic properties of tau and its interactions with other pathologies. Winners will collectively receive over <span class=\"xn-money\">$2 million<\/span> to fund their proposed neurodegenerative research.<\/p>\n<p><b>About the Rainwater Charitable Foundation&#8217;s Medical Research<\/b><br \/>The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist\u00a0Richard E. Rainwater. When Richard was diagnosed with a rare neurodegenerative disease and primary tauopathy called Progressive Supranuclear Palsy (PSP), the RCF expanded its mission to accelerate the development of new diagnostics and treatments for tau-related neurodegenerative disorders. The RCF Medical Research Team supports this focus by managing the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=603781529&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2Fthe-tau-consortium%2F&amp;a=Tau+Consortium\" target=\"_blank\" rel=\"nofollow\">Tau Consortium<\/a>, the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=4217376304&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2Fthe-rainwater-prize%2F&amp;a=Rainwater+Prize+Program\" target=\"_blank\" rel=\"nofollow\">Rainwater Prize Program<\/a>\u00a0and the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=328178424&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2Fadditional-research-programs%2Fworkshop%2F&amp;a=Tauopathy+Challenge+Workshop\" target=\"_blank\" rel=\"nofollow\">Tauopathy Challenge Workshop<\/a>. With over\u00a0$140 million\u00a0invested in medical research to date, the RCF has helped to advance eight treatments into human trials. Currently the RCF supports a range of programs, including a focus on family economic security, medical research and other worthy causes. For more information, please visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=4060234300&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4091598-1%26h%3D554174971%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3766179-1%2526h%253D1091519000%2526u%253Dhttps%25253A%25252F%25252Frainwatercharitablefoundation.org%25252F%2526a%253Drainwatercharitablefoundation.org%26a%3Drainwatercharitablefoundation.org&amp;a=rainwatercharitablefoundation.org\" target=\"_blank\" rel=\"nofollow\">rainwatercharitablefoundation.org<\/a>.\u00a0<\/p>\n<p><b>About the Aging Mind Foundation<br \/><\/b>The Aging Mind Foundation (AMF) raises money to fund scientific research that seeks the causes of Alzheimer&#8217;s disease and other types of dementia. Since 2013, AMF has awarded significant grants to support innovative research with the ultimate goal of discovering a cure. By investing in discovery and innovation, AMF is committed to reducing the devastating impact of dementia on individuals, families, and communities. Aging Mind Foundation is a project of Players Philanthropy Fund, Inc., a <span class=\"xn-location\">Texas<\/span> nonprofit corporation recognized by IRS as a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code (Federal Tax ID: 27-6601178). To learn more, visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=3370828512&amp;u=https%3A%2F%2Fwww.agingmindfoundation.org%2F&amp;a=www.agingmindfoundation.org\" target=\"_blank\" rel=\"nofollow\">www.agingmindfoundation.org<\/a>.<\/p>\n<p><b>About the Alzheimer&#8217;s Association<br \/><\/b>The Alzheimer&#8217;s Association is a worldwide voluntary health organization dedicated to Alzheimer&#8217;s care, support and research. Our mission is to lead the way to end Alzheimer&#8217;s and all other dementia \u2014 by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer&#8217;s and all other dementia\u00ae. Visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=2304563390&amp;u=http%3A%2F%2Fwww.alz.org%2F&amp;a=alz.org\" target=\"_blank\" rel=\"nofollow\">alz.org<\/a>\u00a0or call 800.272.3900.<\/p>\n<p><b>About CurePSP<br \/><\/b>CurePSP is the leading nonprofit organization dedicated to the awareness, care and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). As a catalyst for new treatments and a cure, CurePSP establishes important partnerships and funds critical research internationally. Through its advocacy and support efforts, CurePSP enhances education, care delivery and quality of life for people living with PSP, CBD and MSA and their families. Science, community and hope are at the heart of CurePSP&#8217;s mission and all its services. CurePSP is a registered 501(c)(3) charity within the United States (EIN: 52-1704978).\u00a0For more information, please visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=3405988779&amp;u=https%3A%2F%2Fwww.psp.org%2F&amp;a=www.psp.org\" target=\"_blank\" rel=\"nofollow\">www.psp.org<\/a>.<\/p>\n<p><b>Corporate Contact:\u00a0<\/b><br \/>Jordan Brainerd\u00a0<br \/>The Rainwater Charitable Foundation<br \/><a href=\"mailto:jbrainerd@rainwatercf.org\" target=\"_blank\" rel=\"nofollow\">jbrainerd@rainwatercf.org\u00a0<br \/><\/a>(817) 820-2708\u00a0<\/p>\n<p><b>Media Contact:<\/b> <br \/><span class=\"xn-person\">Kerry Sinclair<\/span> <br \/>Spectrum Science <br \/><a href=\"mailto:ksinclair@spectrumscience.com\" target=\"_blank\" rel=\"nofollow\">ksinclair@spectrumscience.com<\/a>\u00a0<br \/>(202) 587-1507<\/p>\n<p>Logo &#8211; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=2558400254&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2748989%2FTauopathy_Challenge_Workshop_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2748989%2FTauopathy_Challenge_Workshop_Logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnasia.com\/media2\/2748989\/Tauopathy_Challenge_Workshop_Logo.jpg?p=medium600<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2748989\/Tauopathy_Challenge_Workshop_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"prntac\"><i>Established in 2023, the Tauopathy Challenge Workshop aims to bridge the gap in funding of novel neurodegenerative research for primary tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs).<\/i><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">FORT WORTH, Texas<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 13, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=1918150831&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2F&amp;a=The+Rainwater+Charitable+Foundation\" target=\"_blank\" rel=\"nofollow\">The Rainwater Charitable Foundation<\/a>, one of the largest independent funders of primary tauopathy research, in collaboration with the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=235016787&amp;u=https%3A%2F%2Fagingmindfoundation.org%2F&amp;a=Aging+Mind+Foundation\" target=\"_blank\" rel=\"nofollow\">Aging Mind Foundation<\/a>, the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=3063617718&amp;u=https%3A%2F%2Fwww.alz.org%2F&amp;a=Alzheimer%27s+Association\" target=\"_blank\" rel=\"nofollow\">Alzheimer&#8217;s Association<\/a>, and <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=3061121997&amp;u=https%3A%2F%2Fwww.psp.org%2F&amp;a=CurePSP\" target=\"_blank\" rel=\"nofollow\">CurePSP<\/a>,\u00a0announced today <span class=\"xn-money\">$2.5 million<\/span> in grants to fund five innovative research projects over the course of two years emerging from the second annual <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=943107863&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2F2025-tauopathy-challenge-workshop-participants-will-explore-the-role-of-copathologies-in-primary-tauopathies%2F&amp;a=Tauopathy+Challenge+Workshop\" target=\"_blank\" rel=\"nofollow\">Tauopathy Challenge Workshop<\/a>.<\/p>\n<p>The Tauopathy Challenge Workshop is a funding program that convenes interdisciplinary experts around a single topic, addressing unmet needs in primary tauopathies. By funding innovative research, it aims to support the development of treatments for these debilitating neurodegenerative diseases, such as Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs).<\/p>\n<p>Growing in size and impact since its inception in 2023, the Tauopathy Challenge Workshop has awarded <span class=\"xn-money\">$4.5 million<\/span> to support novel, mechanism-focused research aimed at uncovering new therapeutic and biomarker targets for these tau-driven neurodegenerative diseases. This year, five groundbreaking projects will be funded and led by esteemed international researchers:<\/p>\n<ul type=\"disc\">\n<li><b>Eleanor\u00a0Drummond, PhD, <span class=\"xn-org\">University of Sydney<\/span><\/b>\u00a0<b>(Awarded <span class=\"xn-money\">$500,000<\/span>): <\/b>This research aims to uncover how abnormal protein aggregation beyond tau contributes to primary tauopathies, specifically PSP, CBD, and Pick&#8217;s disease. Using advanced molecular techniques, Dr. Drummond will identify proteins in the human brain prone to forming pathological aggregates and determine whether these changes are shared across different tauopathies. By mapping the location of these proteins in brain tissue and testing whether tau drives their aggregation, the study seeks to clarify disease mechanisms, identify biomarkers, and explore whether these processes can be reversed in cell models\u2014ultimately guiding future therapeutic strategies.<\/li>\n<li><b><span class=\"xn-person\">Leonard Petrucelli<\/span>, PhD, Mayo Clinic (Awarded <span class=\"xn-money\">$500,000<\/span>):\u00a0<\/b>This research explores whether lysosomal transmembrane protein <span class=\"xn-money\">106B<\/span> (TMEM106B) fibrils promote tau seeding and worsen PSP symptoms, by analyzing post-mortem brain samples and assessing correlations between protein levels, genetic variants, and disease severity. Using innovative tools in human neurons and mouse models, Dr. Petrucelli and his co-investigator, Dr. <span class=\"xn-person\">Michael Ward<\/span> (National Institutes of Health), will test whether TMEM106B fibrils directly influence tau pathology and lysosomal dysfunction, potentially uncovering new mechanisms and therapeutic targets for PSP.<\/li>\n<li><b><span class=\"xn-person\">Vijay Rangachari<\/span>, PhD, The <span class=\"xn-org\">University of Southern Mississippi<\/span> (Awarded <span class=\"xn-money\">$500,000<\/span>):\u00a0<\/b>This research examines the potential interaction between two amyloid-forming proteins\u2014transactive response DNA binding protein 43 kDa (TDP-43) and tau\u2014in neurodegenerative diseases such as PSP and frontotemporal lobar degeneration (FTLD). While both proteins are known to independently form toxic aggregates, the work explores whether they can co-aggregate into &#8220;hybrid amyloids&#8221; with unique structures and pathological effects. Dr. Rangachari aims to confirm the presence of these deposits in human brain tissue, understand their molecular characteristics, and assess their role in neuronal dysfunction\u2014with the hope of developing antibodies to detect these toxic agents in the brain.<\/li>\n<li><b>Wilfried Rossoll, PhD, Mayo Clinic (Awarded <span class=\"xn-money\">$500,000<\/span>): <\/b>This research aims to uncover how TDP-43 co-pathology influences tau pathology and contributes to neurodegeneration in PSP and CBD. By leveraging both innovative spatial proteomics discovery approaches in human post-mortem brain tissue and mechanistic studies in mouse brain tissue culture models, Dr. Rossoll will explore how these proteins interact and affect overall disease progression. Insights gained will pave the way for stronger tools for studying neurodegenerative disorders and developing effective treatments.<\/li>\n<li><b><span class=\"xn-person\">Mikael Simons<\/span>, MD, Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen, DZNE (German Center for Neurodegenerative Diseases) (Awarded <span class=\"xn-money\">$500,000<\/span>): <\/b>This research investigates how non-neuronal cells, particularly glial cells like oligodendrocytes, and factors such as myelin damage and lipoproteins (particularly ApoE), contribute to tau aggregation and propagation. Using advanced imaging, biochemical assays, and both mouse models and human brain tissue, Dr. Simons aims to uncover whether disruptions in myelin and lipid transport systems play a critical role in tau pathology. The goal is to deepen understanding of tau-related disorders and identify potential therapeutic targets.<\/li>\n<\/ul>\n<p>&#8220;We&#8217;re encouraged to see growing momentum around the Tauopathy Challenge Workshop, with partners such as the Aging Mind Foundation, the Alzheimer&#8217;s Association, and CurePSP joining our mission to support these novel, high impact proposals,&#8221; said <span class=\"xn-person\">Jeremy Smith<\/span>, President of the Rainwater Charitable Foundation. &#8220;Given the current constraints on research funding, our commitment remains steadfast in advancing primary tauopathy research. The insights gained from this workshop have the potential to significantly impact broader neurodegenerative disease research, bringing us closer to meaningful treatments for those affected.&#8221;<\/p>\n<p>The 2026 Tauopathy Challenge Workshop is open to all researchers through a letter of intent process, with <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=331493903&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2Fadditional-research-programs%2Fworkshop%2F&amp;a=applications\" target=\"_blank\" rel=\"nofollow\">applications<\/a>\u00a0for the next workshop open through <span class=\"xn-chron\">September 2, 2025<\/span>. The 2026 session is focused on exploring the structural and thermodynamic properties of tau and its interactions with other pathologies. Winners will collectively receive over <span class=\"xn-money\">$2 million<\/span> to fund their proposed neurodegenerative research.<\/p>\n<p><b>About the Rainwater Charitable Foundation&#8217;s Medical Research<\/b><br \/>The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist\u00a0Richard E. Rainwater. When Richard was diagnosed with a rare neurodegenerative disease and primary tauopathy called Progressive Supranuclear Palsy (PSP), the RCF expanded its mission to accelerate the development of new diagnostics and treatments for tau-related neurodegenerative disorders. The RCF Medical Research Team supports this focus by managing the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=603781529&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2Fthe-tau-consortium%2F&amp;a=Tau+Consortium\" target=\"_blank\" rel=\"nofollow\">Tau Consortium<\/a>, the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=4217376304&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2Fthe-rainwater-prize%2F&amp;a=Rainwater+Prize+Program\" target=\"_blank\" rel=\"nofollow\">Rainwater Prize Program<\/a>\u00a0and the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=328178424&amp;u=https%3A%2F%2Frainwatercharitablefoundation.org%2Fmedical-research-program%2Fadditional-research-programs%2Fworkshop%2F&amp;a=Tauopathy+Challenge+Workshop\" target=\"_blank\" rel=\"nofollow\">Tauopathy Challenge Workshop<\/a>. With over\u00a0$140 million\u00a0invested in medical research to date, the RCF has helped to advance eight treatments into human trials. Currently the RCF supports a range of programs, including a focus on family economic security, medical research and other worthy causes. For more information, please visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=4060234300&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4091598-1%26h%3D554174971%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3766179-1%2526h%253D1091519000%2526u%253Dhttps%25253A%25252F%25252Frainwatercharitablefoundation.org%25252F%2526a%253Drainwatercharitablefoundation.org%26a%3Drainwatercharitablefoundation.org&amp;a=rainwatercharitablefoundation.org\" target=\"_blank\" rel=\"nofollow\">rainwatercharitablefoundation.org<\/a>.\u00a0<\/p>\n<p><b>About the Aging Mind Foundation<br \/><\/b>The Aging Mind Foundation (AMF) raises money to fund scientific research that seeks the causes of Alzheimer&#8217;s disease and other types of dementia. Since 2013, AMF has awarded significant grants to support innovative research with the ultimate goal of discovering a cure. By investing in discovery and innovation, AMF is committed to reducing the devastating impact of dementia on individuals, families, and communities. Aging Mind Foundation is a project of Players Philanthropy Fund, Inc., a <span class=\"xn-location\">Texas<\/span> nonprofit corporation recognized by IRS as a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code (Federal Tax ID: 27-6601178). To learn more, visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=3370828512&amp;u=https%3A%2F%2Fwww.agingmindfoundation.org%2F&amp;a=www.agingmindfoundation.org\" target=\"_blank\" rel=\"nofollow\">www.agingmindfoundation.org<\/a>.<\/p>\n<p><b>About the Alzheimer&#8217;s Association<br \/><\/b>The Alzheimer&#8217;s Association is a worldwide voluntary health organization dedicated to Alzheimer&#8217;s care, support and research. Our mission is to lead the way to end Alzheimer&#8217;s and all other dementia \u2014 by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer&#8217;s and all other dementia\u00ae. Visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=2304563390&amp;u=http%3A%2F%2Fwww.alz.org%2F&amp;a=alz.org\" target=\"_blank\" rel=\"nofollow\">alz.org<\/a>\u00a0or call 800.272.3900.<\/p>\n<p><b>About CurePSP<br \/><\/b>CurePSP is the leading nonprofit organization dedicated to the awareness, care and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). As a catalyst for new treatments and a cure, CurePSP establishes important partnerships and funds critical research internationally. Through its advocacy and support efforts, CurePSP enhances education, care delivery and quality of life for people living with PSP, CBD and MSA and their families. Science, community and hope are at the heart of CurePSP&#8217;s mission and all its services. CurePSP is a registered 501(c)(3) charity within the United States (EIN: 52-1704978).\u00a0For more information, please visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=3405988779&amp;u=https%3A%2F%2Fwww.psp.org%2F&amp;a=www.psp.org\" target=\"_blank\" rel=\"nofollow\">www.psp.org<\/a>.<\/p>\n<p><b>Corporate Contact:\u00a0<\/b><br \/>Jordan Brainerd\u00a0<br \/>The Rainwater Charitable Foundation<br \/><a href=\"mailto:jbrainerd@rainwatercf.org\" target=\"_blank\" rel=\"nofollow\">jbrainerd@rainwatercf.org\u00a0<br \/><\/a>(817) 820-2708\u00a0<\/p>\n<p><b>Media Contact:<\/b> <br \/><span class=\"xn-person\">Kerry Sinclair<\/span> <br \/>Spectrum Science <br \/><a href=\"mailto:ksinclair@spectrumscience.com\" target=\"_blank\" rel=\"nofollow\">ksinclair@spectrumscience.com<\/a>\u00a0<br \/>(202) 587-1507<\/p>\n<p>Logo &#8211; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4486754-1&amp;h=2558400254&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2748989%2FTauopathy_Challenge_Workshop_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2748989%2FTauopathy_Challenge_Workshop_Logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnasia.com\/media2\/2748989\/Tauopathy_Challenge_Workshop_Logo.jpg?p=medium600<\/a>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-30043","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/30043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30043"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/30043\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}